Am J Transplant, Volume 17, Suppl 3 Archives - Page 153 of 181 - ATC Abstracts

2017 American Transplant Congress
Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients.
M. Marron-Wojewodzki,¹ I. Szwarc,¹ C. Rene,² G. Mourad,¹ M. Le Quintrec.^1,3
¹Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier, France; ²Departement of Immunology, Hôpital Saint Eloi, Montpellier, France; ³Inserm U1183,, IRMB,Hôpital Saint Eloi, Montpellier, France
Background.Development of de novo donor specific antibodies (dnDSA) concerns about 10% of patients within the first year following kidney transplantation and reach about 20% within…
2017 American Transplant Congress
Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).
C. Danthu,¹ M. Gomes-Mayeras,¹ D. Andouard,² E. Munteanu,¹ R. Moulinas,^1,4 G. Ligat,² S. Hantz,^1,2 J. Rerolle,³ F. Garnier,¹ M. Essig,³ S. Alain.^1,2,4
¹National Reference Center for CMV-Virology, CHU Limoges, Limoges, France; ²UMR Inserm 1092, Université Limoges, Limoges, France; ³Nephrology, CHU Limoges, Limoges, France; ⁴GenoLim/Biscem Genomic Platform, Université Limoges, Limoges, France
Results from the French Cohorts 2006-2010 and OrphaVic (NCTNCT02067169) indicates that fifty percent of graft failures in renal recipients infected by HCMV after treatment with…
2017 American Transplant Congress
mTOR Inhibition Diminishes Peripheral Blood CD8⁺CD28^–CD38^hi Effector/Memory T Cells and Facilitates Resolution of Belatacept-Refractory Kidney Rejection.
C. Castro-Rojas,¹ A. Godarova,¹ A. Leino,² R. Alloway,² M. Jordan,³ E. Woodle,² D. Hildeman.¹
¹Division of Immunobiology, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH; ²Division of Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH; ³Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Research Foundation, Cincinnati, OH
Belatacept, a CD28-CD80/86 blocker, was approved by the FDA to provide immunosuppression without nephrotoxicity or cardiovascular and metabolic adverse effects. As part of our multi-center…
2017 American Transplant Congress
Advanced Donation within a Paired Exchange Program.
M. Charlton,¹ F. Desrosiers,¹ G. Bretzlaff,¹ D. Serur.²
¹Kidney and Pancreas Transplant Program, New York Presbyterian Weill Cornell, New York, NY; ²Division of Nephrology and the Rogosin Institute, New York Presbyterian Weill Cornell, New York, NY
BACKGROUND:Advanced Donation (ADP) within Kidney Paired Donation (KDP) occurs when a donor is time-limited and chooses to donate a kidney before their intended recipient with…
2017 American Transplant Congress
Tacrolimus Time in Therapeutic Range Predicts Adverse Clinical Outcomes in the First Year of Kidney Transplant.
S. Davis, J. Gralla, P. Klem, A. Wiseman, J. Cooper.
University of Colorado, Aurora, CO
Tacrolimus (TAC) has a narrow therapeutic range, with its upper bounds limited by serious toxicities while TAC minimization strategies have demonstrated immunologic risk. Monitoring the…
2017 American Transplant Congress
A Possible Unintended Consequence of the Kidney Allocation System: The Effect of Duration of Dialysis on Mental Health Outcomes.
S. Radomski,^1,2 I. Feurer,² R. Forbes,² B. Concepcion,² H. Schaefer.²
¹Georgetown University School of Medicine, Washington, DC; ²Vanderbilt University Medical Center, Nashville, TN
Purpose: Long-term dialysis has been shown to adversely affect physical health-related quality of life (HRQOL) but its effect on mental HRQOL and symptoms of depression…
2017 American Transplant Congress
Induction of Proliferative Responses in B Cell and Plasma Cell Populations Following Proteasome Inhibitor Desensitization Treatment in Rhesus Macacques and Humans.
J. Driscoll,¹ S. Knechtle,² J. Kwun,² S. Tremblay,¹ N. Salomonis,³ S. Potter,³ B. Aronow,³ M. Manook,² R. Alloway,¹ H. Singh,³ E. Woodle.¹
¹U of Cincinnati, Cincinnati; ²Duke, Durham; ³Cincinnati Childrens, Cincinnati
Proteasome inhibitor (PI)-based desensitization (DS) in humans has demonstrated variable reduction in HLA antibody levels that is often associated with variable rebound following treatment cessation.The…
2017 American Transplant Congress
Reduction in Kidney Offer Acceptance at Centers Undergoing Systems Improvement Agreements.
M. Bowring, L. Nicholas, A. Massie, D. Segev.
JHU, Baltimore
Kidney transplant centers flagged twice by CMS for poor outcomes enter a Systems Improvement Agreement (SIA) if they fail to demonstrate mitigating factors. Motivated to…
2017 American Transplant Congress
Share35: Increasing Biliary Complications and Healthcare Resources?
J. Fleming,¹ C. Perez,¹ M. Sobhanian,¹ D. Taber,² G. Chedister,² D. Axelrod,³ K. Chavin.²
¹Pharmacy, Medical University of South Carolina, Charleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC; ³Surgery, East Carolina University, Greenville, NC
Data has shown that major outcomes of liver transplant post-Share35 have been equivalent to pre-Share35, despite organs accumulating longer CIT and traveling further.The PURPOSE of…
2017 American Transplant Congress
Addition of FEV1 Drop to LAS May Improve Access of CF Patients to Transplant: Analysis of the SRTR and US CF Foundation Patient Registries.
E. Dasenbrook,¹ M. Skeans,² A. Fink,³ B. Marshall,³ M. Valapour.^1,2
¹Cleveland Clinic, Cleveland; ²SRTR, Minneapolis; ³CF Foundation, Bethesda
Lung transplant is a widely accepted treatment for cystic fibrosis (CF) end-stage lung disease. The US lung allocation score (LAS) system prioritizes transplant candidates primarily…